A podcast (and other things!) for physicians who are interested in evidence based medicine and rheumatology
New myositis drugs are easy to overread from the headline result alone. This review separates skin response, muscle response, steroid sparing, infection risk, and the unanswered question of where brepocitinib sits beside IVIG and conventional DMARDs.
.svg)